Table 2 Effectiveness of PJP prophylaxis among different rheumatic diseases
Diagnosis | Total | Ever PJP | No PJP | ARR (%) | NNT |
|---|---|---|---|---|---|
All patients | 21,587 | 48 | 21,540 | 435 | |
Prophylaxis | 0 | 1142 | 0.23 | ||
No prophylaxis | 48 | 20,398 | |||
RA | 11,646 | 13 | 11,633 | 909 | |
Prophylaxis | 0 | 72 | 0.11 | ||
No prophylaxis | 13 | 11,561 | |||
SpA | 2918 | 0 | 2918 | – | – |
Prophylaxis | 0 | 49 | |||
No prophylaxis | 0 | 2869 | |||
SLE | 5460 | 22 | 5438 | 217 | |
Prophylaxis | 0 | 629 | 0.46 | ||
No prophylaxis | 22 | 4809 | |||
IMM | 1026 | 7 | 1019 | 114 | |
Prophylaxis | 0 | 220 | 0.88 | ||
No prophylaxis | 7 | 799 | |||
AAV | 430 | 6 | 424 | 48 | |
Prophylaxis | 0 | 135 | 2.08 | ||
No prophylaxis | 6 | 289 | |||
SSc | 109 | 2 | 107 | 36 | |
Prophylaxis | 0 | 36 | 2.81 | ||
No prophylaxis | 2 | 71 |